Background: The combination of carmustine, etoposide, cytarabine and melphalan (BEAM) is an effective autologous transplantation preparative regimen for lymphoma and has little toxicity, but the feasibility and tolerance of BEAM as a preparative regimen for allogeneic transplantation has not been established.
Introduction
While high-dose chemotherapy and autologous marrow or blood stem cell transplantation is a well-established therapy for high-risk lymphoma, patients with refractory disease or marrow involvement have a poor prognosis [1] . For these individuals, allogeneic transplantation has emerged as a treatment option, with remission rates generally greater than 80%, and long-term disease-free survivals of 18%-54% [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Outcome after allogeneic transplantation varies with lymphoma-related factors such as histologic grade and chemosensitivity at the time of transplantation [8-11, 14, 15, 18] , but treatmentrelated complications rather than relapse are the major cause of treatment failure. Use of allogeneic blood stem cells rather than marrow was associated with a lower risk of severe treatment-related toxicity [16] , but whether blood stem cells will also reduce the relapse rate and improve long-term survival is not known.
The combination of carmustine, etoposide, cytarabine and melphalan (BEAM), a widely-used preparative regimen for autologous transplantation, was designed by Biron et al. [20] to provide antilymphoma activity without the toxicities of cyclophosphamide and total body irradiation (TBI). Following BEAM and autologous transplantation, complete responses were seen in 20%-67% of patients with active lymphoma at the time of transplantation, and disease-free survival has been reported as 23%-62% [20] [21] [22] [23] [24] [25] [26] . With improvements in supportive care, treatment-related mortality with the BEAM regimen has fallen from more than 10% to less than 5% [20] [21] [22] [23] [24] [25] [26] [27] [28] and currently approximates that of standard chemotherapy for advanced lymphoma [28] . The limited morbidity and mortality associated with the BEAM regimen for autologous transplantation has fostered its use as consolidation therapy for patients with newly-diagnosed poor-prognosis lymphoma [25, 27, 28] .
The tolerability of BEAM makes it an attractive preparative regimen for allogeneic transplantation, but the omission of cyclophosphamide and TBI raised concerns regarding the immunosuppressive potency and ability of BEAM to support engraftment of allogeneic hematopoietic stem cells. However, preclinical studies suggested that both carmustine and melphalan have immunosuppressive activity [29] , and melphalan alone at 240 mg/m 2 [30] or at a dose of 140 mg/m 2 in combination with busulfan [31] has been used successfully as conditioning for a primary marrow allograft. Preliminary experience [32] suggested that the standard BEAM regimen would also support engraftment of allogeneic marrow. We have therefore conducted a Phase II study to evaluate the feasibility and safety of BEAM as a preparative regimen for HLA-identical allogeneic hematopoietic stem-cell transplantation for patients with highrisk lymphoma. patients were followed through day 100 for hemorrhagic cystitis, idiopathic interstitial pneumonitis, and veno-occlusive disease [40] . GVHD was graded according to the consensus criteria [41] . Restaging was scheduled at 1, 3, 6 and 12 months, then annually after transplantation. A complete response after transplantation was defined as complete resolutions of manifestation of lymphoma or minimal residual radiographic abnormalities that were gallium-negative, and these findings must have remained so between at least two evaluations or at autopsy.
Patients and methods

Patients
Eligible patients had biopsy-proven lymphoma and failed to achieve a complete response to primary chemotherapy or relapsed after first remission. Additional eligibility criteria included a life expectancy of at least 12 weeks, Zubrod performance status ^ 2, at least four weeks from prior therapy, total bilirubin < 1.5 mg/dl, alanine transferase ^ 3 times the upper limit of normal, and creatinine ^1.5 mg/dl. Patients with uncontrolled arrhythmias or symptomatic cardiac disorders, FEV1, FVC and DLCO < 50% of expected, symptomatic pulmonary disease, central nervous system involvement, and HIV or HTLV-1 seropositivity were ineligible. The protocol was approved by the Institutional Review Board of the M.D. Anderson Cancer Center, and written informed consent was obtained from each patient. From November 1995 through January 1998, thirty patients with HLA-identical donors were transplanted on this study. 
Transplantation and supportive care
Day 0 is the day of transplantation. Marrow was harvested and processed for ABO-incompatibility by standard measures when necessary. Blood stem cells were collected from filgrastim-mobilized donors by apheresis and cryopreserved as reported [33] . None of the transplants was depleted of T cells. All patients received filgrastim 5 ug/kg/d s.c. from day 7 after transplantation through engraftment. GVHD prophylaxis consisted of tacrolimus and methotrexate as described previously [34] . For marrow transplant recipients, methotrexate 5 mg/m 2 i.v. was given on days 1, 3, 6 and 11, and blood stem-cell recipients received methotrexate only on days 1, 3 and 6. Other details of supportive care measures, including prophylactic antibiotics and transfusion policies, have been published [35] .
Study definitions
Histologic diagnosis and grade of lymphoma was made on the basis of the updated Working Formulation [36] . Patients were also categorized by the standard Ann Arbor stage, International Prognostic Index [37] and M.D. Anderson Tumor Score [38] . Neutrophil recovery was defined as the first of three consecutive days that the absolute neutrophil count (ANC) exceeded the target number (0.5 or 1.0 x 10 9 /l), and platelet recovery was defined as the day that the platelet count exceeded the target number (20 or 50 x 1O 9 /1) with no platelet transfusions the following week. Hematopoietic chimerism was evaluated by restriction fragment length polymorphisms at the AY-29 or YNH24 loci as described [39] . Early preparative regimen-related toxicity (RRT) was graded according to the Seattle criteria, except that
Statistical considerations
At the time of analysis, median time from transplantation was 20 months (range 6-32 months). The primary objective of this phase II study to determine the feasibility and tolerance of the BEAM regimen. Assessment of antilymphoma activity was a secondary objective. Actuarial estimates of times to engraftment, discharge, GVHD, relapse and death were calculated according to the method of , and comparisons were made using the log-rank test. All /"-values are two-sided, and a /"-value <0.05 was considered significant.
Results
Patients
Characteristics of the thirty patients are shown in Table 1 . Nineteen patients had intermediate-grade lymphoma, and eleven had low-grade lymphoma. Three had a T-cell phenotype, twenty-five had a B-cell phenotype, and two were not studied. Five had a transformed lymphoma. All three mantle cell lymphomas were of the diffuse type. There was a median of 18 months (range 4-185 months) between diagnosis and transplantation. Eleven patients had received bleomycin, and six had prior mediastinal irradiation or TBI. One patient had relapsed after autologous transplantation, one after allogeneic transplantation, and two after allogeneic minitransplantation with rejection. At the time of transplantation in the present study, three patients were in remission, 10 had a partial remission to chemotherapy, six had stable disease, seven had progressive disease despite treatment with conventional chemotherapy, and four were untreated. Of the patients with active disease, two had stage II, six had stage III, and nineteen had stage IV disease. Thirteen patients had marrow involvement. The median Zubrod performance status was 1 (range 0-2). prior to day 100 without platelet recovery. For the remainder of the patients, median times to platelet recovery were 16 (range 10-28) days for a platelet count >20 x 1O 9 /1, and 21 (range 14-36) days for a platelet count ^ 50 x 10 9 /l. Two patients failed to have neutrophil recovery after transplantation. One had primary graft failure. She was reconditioned with ATG prior to infusion of a second blood stem cell transplant on day 28 and engrafted, but she expired from disseminated toxoplasmosis on day 95. There was no histologic or immunocytochemical evidence of toxoplasmosis in marrow samples taken before the second transplant. The other patient had persistent lymphoma in the marrow and peripheral blood posttransplant; he was reconditioned with fludarabine and ATG with infusion of a second blood stem cell transplant on day 41, but he expired on day 54 without hematologic recovery.
Ten patients failed to clear lymphoma from the marrow, had graft failure, could not be distinguished from the donor by the tests done, or expired early and were not tested. For the other twenty patients, cytogenetics and/or RFLP analysis demonstrated complete chimerism in 19 studied in remission within three months after transplantation. The remaining patient had hematopoietic recovery, but he was unexpectedly found to have recipient-derived hematopoiesis by RFLP analysis at three months posttransplant; he relapsed 11 months later. Complete donor chimerism persisted in 10 of 10 patients tested one to two years posttransplant.
Regimen-related toxicity
Eighty-three percent of patients were discharged from hospital, and the median time of discharge was day 21 (range days 13-34) after transplantation. Four (13%) patients developed a grade 3-4 RRT ( Table 2 ). The median cumulative toxicity score was 3 (range 1-14), and only four patients had a cumulative toxicity scorê 7. Mucositis was mild; only 11 (37%) had grade 2 stomatitis, and none had more than grade 1 enteritis. Two patients had idiopathic pneumonitis, only one of whom responded to treatment with corticosteroids. Seven other patients were intubated for respiratory insufficiency; one had cardiogenic pulmonary edema, one had CMV pneumonia, one had toxoplasmosis, and four were septic. There was no correlation between respiratory insufficiency and prior bleomycin use or mediastinal irradiation. Mild elevation of transaminases were common, and one patient had fatal veno-occlusive disease. Four patients had hemorrhagic cystitis, only two of which occurred before day 30. One patient had a seizure thought to be due to carmustine. Two patients had hemolytic uremic syndrome, but it was not clear whether this was related to the preparative regimen.
Graft-vs. -host disease
The full scheduled dose of methotrexate was administered to all of the blood stem-cell recipients and four of the six marrow recipients. The actuarial rate of grade 2-4 GVHD was 31% (95% CI: 13%-49%), and that of grade 3-4 GVHD was 16% (95% CI: 1%-31%). Nineteen patients survived in remission until at least 100 days after transplantation; the actuarial rate of chronic GVHD at one-year was 54% (95% CI: 30%-77%).
